Record overview
Status and phase
Status: RECRUITING
Phase: PHASE2
Sponsor: University of California, San Francisco
Condition: Neuroendocrine Tumors, Well-Differentiated Neuroendocrine Carcinoma, High Grade Neuroendocrine Carcinoma, Any Site
NCT05746208
Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors
Public trial-level signal summary for this oncology Phase 2 record.
Signal summary
Public flags
Status signal: Low Signal
Timeline signals: long_recruitment_duration_signal
Results signal: Low Signal
Operational burden: strict_eligibility_signal
Stopped reason
Context when available
No stop reason available in the current public record.